Tumor vaccines induce or enhance the body's specific active immune response against tumor antigens, thereby controlling and killing tumor cells, clearing minimal residual lesions, and establishing persistent anti-tumor memory. It is one of the most advanced technological routes in the field of tumor therapy. Tumor mRNA therapeutic vaccines have adjuvant effects and can efficiently express multiple antigens simultaneously. They have the advantages of strong immunogenicity and high efficacy, as well as low production costs and short development cycles, meeting the needs of personalized customization. They have achieved numerous disruptive results in clinical research1.
We offer comprehensive, proprietary intellectual property solutions covering the entire value chain from tumor antigen screening and prediction to clinical sample production and regulatory submission. Clients can choose from integrated solutions or individual modules/technical points according to their specific needs, including tumor neoantigen prediction, design and synthesis of multi-cistronic mRNA (expression of multiple antigens), immunostimulatory cap analogs, targeted LNP delivery systems, and immunostimulatory UTR and poly A tails. Leveraging proprietary intellectual property technologies, critical raw materials, and research and development production equipment supply chains, EnoBio can not only address the stability and comprehensive cost challenges of mRNA vaccines but also meet various demands for the development of vaccines with full intellectual property control.